Algiax Appoints Dr. Daniel Gau as Chief Business Officer
Düsseldorf, GERMANY – December 18, 2025 – Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced the
Düsseldorf, GERMANY – December 18, 2025 – Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced the
Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm
Last patient out achieved Topline data expected by end of November 2024 AP-325 is a small molecule aimed at reducing neuropathic pain by activating GABAA
Initiation of 12 new clinical sites in Belgium and France in addition to the active sites in Spain and Czech Republic The study is continuing
— Data Monitoring Committee recommends continuation of the study with no safety alerts within the study population — Company is ramping up patient recruitment by
Great news from Algiax – our peer-reviewed publication on one of our novel positive allosteric modulators of the GABAA-receptor, the thioacrylamide HK4, is now available
DÜSSELDORF, Germany–(BUSINESS WIRE)–Algiax Pharmaceuticals, a clinical-stage biotechnology company focused on development of GABAA receptor modulators for neuropathic pain and other indications with unmet medical need, announced
Algiax Pharmaceuticals finalizes financing round and welcomes OCCIDENT and a German family office as new investors on board. DÜSSELDORF, Germany–(BUSINESS WIRE)–Algiax Pharmaceuticals, a clinical-stage biotechnology
Clinical neuropathic pain expert Prof. Sommer and long-time pain pharma industry expert Dr. Langner to consult Algiax Pharmaceuticals in the development of AP-325 and further
Algiax Pharmaceuticals Appoints Dr. Ingo Lehrke and Dr. Guido Koopmans as CEO and CSO. A Proof-of-Concept Study for Neuropathic Pain is planned to start in
Algiax Pharmaceuticals is founding partner of the new Center of Competence for Innovative Diabetes Therapy (KomIT) funded by NRW and EU March 27, 2019, Erkrath,
End of June 2016 Algiax started a collaboration program to perform a preclinical Proof-of-Concept in Diabetes Type 1 with a selection of Algiax` proprietary new
On December 10th 2015 Algiax got its approval from the German authorities (BfArM) to start the Phase Ib study entitled “Pharmacodynamic Effects of AP-325 in
Today Algiax announces the completion of two successful Phase I trials with their lead compound AP-325. AP-325 was tested in both single and multiple dose
As of June 2015, Algiax initiated a Phase I study with the primary objective to investigate the pharmacokinetics, safety, and tolerability of multiple ascending doses
In August 2013 our lead compound AP-325 received Orphan Drug Designation from EMA for the treatment of traumatic spinal cord injury.
Use of SalesViewer® technology:
This website uses SalesViewer® technology from SalesViewer® GmbH on the basis of the website operator’s legitimate interests (Section 6 paragraph 1 lit.f GDPR) in order to collect and save data on marketing, market research and optimisation purposes.
In order to do this, a javascript based code, which serves to capture company-related data and according website usage. The data captured using this technology are encrypted in a non-retrievable one-way function (so-called hashing). The data is immediately pseudonymised and is not used to identify website visitors personally
The data stored by Salesviewer will be deleted as soon as they are no longer required for their intended purpose and there are no legal obligations to retain them.
The data recording and storage can be repealed at any time with immediate effect for the future, by clicking on https://www.salesviewer.com/opt-out in order to prevent SalesViewer® from recording your data. In this case, an opt-out cookie for this website is saved on your device. If you delete the cookies in the browser, you will need to click on this link again.
You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Google Maps. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information